 Shares of iRadimed NASDAQ:IRMD rose 0.2 after the company reported Q1 results.Quarterly Results Earnings per share were up 38.46 year over year to 0.18, which beat the estimate of 0.15.Revenue of 8,678,000 up by 2.84 from the same period last year, which missed the estimate of 9,660,000.Guidance iRadimed hasnt issued any earnings guidance for the time being.iRadimed hasnt issued any revenue guidance for the time being.Details Of The Call Date: Apr 30, 2020View more earnings on IRMDTime: 12:01 PM ETWebcast URL: Action Companys 52-week high was at 29.74Companys 52-week low was at 14.41Price action over last quarter: down 18.00Company Overview iRadimed Corp is a US-based company that mainly develops, manufactures, markets and distributes a Magnetic Resonance Imaging MRI compatible intravenous IV infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.See more from Benzinga Recap: Silicom Q1 Earnings Proto Labs: Q1 Earnings Insights Recap: Hilton Grand Vacations Q1 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 